Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2001 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
Aventis Pharmaceuticals
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: September 9, 2005
Last updated: February 13, 2006
Last verified: September 2001
Comparison of two combination chemotherapies in the treatment of patients with SLCL

Condition Intervention Phase
Small Cell Lung Cancer
Drug: Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage

Resource links provided by NLM:

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Primary Endpoint:
  • Documentation of the remission rate ( Phase II)
  • Determination of progress free time (Phase III)

Secondary Outcome Measures:
  • Secondary Endpoint:
  • Documentation of progress free time (Phase II)
  • Documentation of objective remission rate ( Phase III)
  • Documentation of 1-year survival rate
  • Documentation of safety of the drug combination

Estimated Enrollment: 286
Study Start Date: October 2001
Estimated Study Completion Date: December 2006
Detailed Description:

Comparison of two combination chemotherapies in the treatment of patients with SLCL

The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cytological or histological proven SCLC Stage I or II at 1st diagnosis
  • no prior chemotherapy
  • measurable tumor disease
  • karnofsky performance 70

Exclusion Criteria:

  • second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)
  • chronic diarrhea, obstructive bowel syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00168896

Contact: Ulrich Keilholz, MD +49-30-8445-3596
Contact: Alexander Schmittel, MD +49-30-8445-3090 alexander.schmittel

Hematology & Oncology Charité CBF Berlin, Germany Recruiting
Berlin, Germany, 12203
Contact: Ulrich Keilholz, MD    +49-30-8445-3596   
Contact: Alexander Schmittel, MD    +49-30-8445-3090   
Principal Investigator: Ulrich Keilholz, MD         
Sponsors and Collaborators
Charite University, Berlin, Germany
Aventis Pharmaceuticals
Principal Investigator: Ulrich Keilholz, MD Charité Campus Benjamin Franklin University Clinic
  More Information Identifier: NCT00168896     History of Changes
Other Study ID Numbers: Haema CBF SCLC UK/AS 01
Study First Received: September 9, 2005
Last Updated: February 13, 2006

Keywords provided by Charite University, Berlin, Germany:

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Carcinoma, Bronchogenic
Bronchial Neoplasms
Etoposide phosphate
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors processed this record on May 25, 2017